Breast cancer organoid model allowed to reveal potentially beneficial combinations of 3,3'-diindolylmethane and chemotherapy drugs

  • Sergey V Nikulin
  • Boris Ya Alekseev
  • Nataliya S Sergeeva
  • Pavel A Karalkin
  • Elizaveta K Nezhurina
  • Valentina A Kirsanova
  • Irina K Sviridova
  • Suraja A Akhmedova
  • Nadezhda N Volchenko
  • Larisa V Bolotina
  • Andrey I Osipyants
  • Dmitry M Hushpulian
  • Maxim A Topchiy
  • Andrey F Asachenko
  • Anastasia P Koval
  • Dmitry S Shcherbo
  • Vsevolod I Kiselev
  • Dmitry S Mikhaylenko
  • Udo Schumacher
  • Andrey A Poloznikov

Abstract

Epigenetic alterations represent promising therapeutic targets in cancer treatment. Recently it was revealed that small molecules have the potential to act as microRNA silencers. Capacity to bind the discrete stem-looped structure of pre-miR-21 and prevent its maturation opens opportunities to utilize such compounds for the prevention of initiation, progression, and chemoresistance of cancer. Molecular simulations performed earlier identified 3,3'-diindolylmethane (DIM) as a potent microRNA-21 antagonist. However, data on DIM and microRNA-21 interplay is controversial, which may be caused by the limitations of the cell lines.

Bibliographical data

Original languageEnglish
ISSN0300-9084
DOIs
Publication statusPublished - 12.2020
PubMed 33098909